NCT07140900View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

March 27, 2028

Study Completion Date

March 30, 2030

Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

Xaluritamig

Participants will receive xaluritamig intravenously.

DRUG

Darolutamide

Participants will receive darolutamide orally.

DRUG

Abiraterone

Participants will receive abiraterone orally.

Trial Locations (4)

2050

RECRUITING

Chris OBrien Lifehouse, Camperdown

2298

RECRUITING

Calvary Mater Newcastle Hospital, Waratah

7000

RECRUITING

Kantonsspital Graubuenden, Chur

55455

RECRUITING

University of Minnesota, Minneapolis

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY